Tags

Type your tag names separated by a space and hit enter

The newer macrolides. Azithromycin and clarithromycin.
Infect Dis Clin North Am. 1995 Sep; 9(3):731-45.ID

Abstract

Azithromycin and clarithromycin are structural analogues of erythromycin that have similar mechanisms of action. The newer macrolides have several distinct advantages over erythromycin, including improved oral bioavailability; longer half-life, allowing once or twice daily administration; higher tissue concentrations; and fewer gastrointestinal adverse effects. Clarithromycin and azithromycin also have enhanced antimicrobial activity. The clinical efficacy of the newer macrolides has been similar to erythromycin for the treatment of upper and lower respiratory tract and skin and soft tissue infections. New therapeutic roles include the use of azithromycin for C. trachomatis infections and the inclusion of clarithromycin or azithromycin as part of therapeutic regimens for disseminated MAC infections in HIV-infected patients. Further clinical trials are needed to determine the optimal roles for and uses of these new macrolides.

Authors+Show Affiliations

Temple University School of Medicine, Philadelphia, Pennsylvania, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

7490441

Citation

Zuckerman, J M., and K M. Kaye. "The Newer Macrolides. Azithromycin and Clarithromycin." Infectious Disease Clinics of North America, vol. 9, no. 3, 1995, pp. 731-45.
Zuckerman JM, Kaye KM. The newer macrolides. Azithromycin and clarithromycin. Infect Dis Clin North Am. 1995;9(3):731-45.
Zuckerman, J. M., & Kaye, K. M. (1995). The newer macrolides. Azithromycin and clarithromycin. Infectious Disease Clinics of North America, 9(3), 731-45.
Zuckerman JM, Kaye KM. The Newer Macrolides. Azithromycin and Clarithromycin. Infect Dis Clin North Am. 1995;9(3):731-45. PubMed PMID: 7490441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The newer macrolides. Azithromycin and clarithromycin. AU - Zuckerman,J M, AU - Kaye,K M, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 731 EP - 45 JF - Infectious disease clinics of North America JO - Infect Dis Clin North Am VL - 9 IS - 3 N2 - Azithromycin and clarithromycin are structural analogues of erythromycin that have similar mechanisms of action. The newer macrolides have several distinct advantages over erythromycin, including improved oral bioavailability; longer half-life, allowing once or twice daily administration; higher tissue concentrations; and fewer gastrointestinal adverse effects. Clarithromycin and azithromycin also have enhanced antimicrobial activity. The clinical efficacy of the newer macrolides has been similar to erythromycin for the treatment of upper and lower respiratory tract and skin and soft tissue infections. New therapeutic roles include the use of azithromycin for C. trachomatis infections and the inclusion of clarithromycin or azithromycin as part of therapeutic regimens for disseminated MAC infections in HIV-infected patients. Further clinical trials are needed to determine the optimal roles for and uses of these new macrolides. SN - 0891-5520 UR - https://www.unboundmedicine.com/medline/citation/7490441/The_newer_macrolides__Azithromycin_and_clarithromycin_ L2 - https://medlineplus.gov/antibiotics.html DB - PRIME DP - Unbound Medicine ER -